With positives like these, longs don't need negatives!
<Few would have expected acceptance>> of the anemia indication? Sez who? In the past few months since Repros talked it up, nobody expressed significant doubt, since the data were strong. So the PR was not a positive surprise.
Your faux-happy story translated into plain English appears to be that Repros's plans are being stymied by the jerks at FDA, so all we can look forward to is a fire sale of the company. Only a vulture fund type could find that cheery.
The best counter to that doom and gloom, IMO, would be a well-reasoned valuation of the anemia indication - you know, the boring stuff: numbers of pts, price per pt, probability of approval by various dates. Then some estimate of what should accrue in a bidding war to the owner of the IP who is not also providing the marketing side. Have to try the same again, but with lower probabilities and longer timeline for the UF chronic and Endo indications, to arrive at fair current valuation of Proellex. Only then can one assess if current mkt cap is a steal or is reasonable.
Sure, it can happen that you can't fund your way there because a low current mkt cap becomes a self-fulfilling trap. It would perhaps be smart for Repros to concentrate funds on getting the anemia trials done and that value proven. However, there's more than one player in women's health and all BPs are desperate for new products, so a fire sales should be avoidable.
News 
Market Data 
Discover 
